Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Mesenchymal stem cells as treatment for MS - progress to date.
Momenta Pharmaceuticals Announces Launch of Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.
Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis.
Zebrafish screen identifies novel compound with selective toxicity against leukemia.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Multiple sclerosis and oligodendroglioma: an exceptional association.
The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2.
DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP).
Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy.
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Multiple sclerosis causing a partial sixth nerve palsy.
Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.
Motor programme activating therapy influences adaptive brain functions in multiple sclerosis: clinical and MRI study.
Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis.
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study.
Activities of daily living: evaluation and treatment in persons with multiple sclerosis.
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
Optic nerve disease and axon pathophysiology.
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
Vitamin A and systemic inflammation as protective factors in multiple sclerosis.
Age-dependent effects on the treatment response of natalizumab in MS patients.
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Pages